COVID Antiviral Paxlovid Provides “No Significant Benefit” to Vaccinated Seniors
Paxlovid, the antiviral drug that became the go-to treatment for SARS-CoV-2 infections during the pandemic, did not reduce hospitalizations or death in older adults who had gotten COVID-19 shots, according to a new study published in the Journal of the American Medical Association (JAMA) last month. Researchers who tested the COVID treatment Paxlovid (nirmatrelvir-ritonavir) on […]
One in Five Paxlovid Users Experience COVID Rebound Infections
A new study published earlier this month suggests that people who took Pfizer’s Paxlovid (nirmatrelvir-ritonavir)—an antiviral drug treatment for COVID-19—are much more likely to experience reinfection than those who did not take the drug. The study, published in the Annals of Internal Medicine, reported that one in five people who take Paxlovid could experience rebound […]
Pfizer Will Charge Patients $1,390 for COVID Anti-Viral Paxlovid
Pfizer, Inc. plans to charge consumers more than double the price charged to the U.S. government for its COVID-19 anti-viral drug nirmatrelvir-ritonavir, sold under the brand name Paxlovid. A five-day course of the drug to treat COVID will soon cost patients $1,390. According to researchers, it costs Pfizer $13 to manufacture the supply of pills […]